Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS.
In an open clinical trial, 109 episodes of Pneumocystis carinii pneumonia (70 proven and 39 highly probable) were treated with clindamycin/primaquine. These episodes were in 35 patients who failed on standard therapy and 15 who did not tolerate standard therapy; 59 patients received this regimen as their initial treatment. The clinical outcome was excellent with only 8 cases of failures encountered (6 patients also failed on standard therapy). The onset of clinical response was obvious in less than 72 hours in 81% of patients; the relapse rate was very low. The regimen was well tolerated and compares advantageously with conventional therapy for Pneumocystis carinii pneumonia.
Toma
E
E
Division of Microbiology, Hôtel-Dieu de Montreal, Quebec, Canada.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology; D011319:Primaquine / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies
D002981:Clindamycin; D011319:Primaquine